Influenza Treatment Market

Market Overview

The global influenza treatment market size was valued at USD 1.07 billion in 2022. It is estimated to reach USD 1.6 billion by 2031, growing at a CAGR of 4.2% during the forecast period (2023–2031).

The anti-influenza drugs refer to pharmaceuticals used to treat people with influenza. Types A, type B, and type C influenza viruses are responsible for the viral infection known as influenza. The virus also severely affects particular populations, including pregnant women, the elderly, young children, and those with chronic illnesses. The infection displays various clinical symptoms, including headache, muscle aches, high fever, and vomiting. As a result, the problem must be treated, which calls for using antiviral medications, including Peramivir, Zanamivir, Oseltamivir Phosphate, and Baloxavir marboxil.

Highlights

• Oseltamivir Phosphatedominates the product segment.
• Hospital Pharmacy dominates the distribution channel segment.
• North America is the highest shareholder in the global market.

Market Dynamics

Market Drivers

Rising R&D Investments for the Discovery of New Drugs

The number of consumers looking for anti-viral medications suitable for treating the influenza virus has increased over the last several months. In addition, there has been a rise in influenza cases around the globe, another important factor that has fueled the demand for the disease's already-existing new and enhanced treatment options. These elements work together to considerably increase the need for new and better sickness treatment choices. There are already a variety of various medications that can be used to treat this sickness, but there is an increasing need for therapies that are more successful than those that are now on the market. As a result, major companies spend a larger percentage of their time and resources researching and developing novel therapeutic options for patients.

Growing Demand for Innovative and Efficient Medications

The rising incidence of the two influenza kinds and the rising desire for more powerful treatments are additional important variables influencing market developments. Since they were first made available to the public, influenza treatments have experienced significant R&D advancements. However, the U.S. Food and Drug Administration (FDA) has only approved four key medications for the treatment of influenza, despite the great potential for market expansion due to unmet patient needs. In addition, there are only a few significant participants in this sector, and the effect of the comparably less expensive generics is growing. However, some strains of the illness are resistant to treatment due to the influenza virus's cyclical nature, and the disease's increasing incidence further deteriorates the prospects for successful patient treatment. This has created a significant unmet treatment need in the market and is expected to be another important driver driving market demand.

Market Restraint

Presence of Substitutes for the Treatment of Influenza

Since influenza infection is lethal if unchecked, treatment is necessary. Numerous sorts of medications can also be used to control this illness. For instance, major players provide vaccines and oral antiviral medications used to treat influenza. Vaccines can also be used to treat influenza instead of oral medications. Fluzone, Flublok, Vaxigrip, and Vaxigrip Tetra are a few of the vaccinations that both GlaxoSmithKline plc and Sanofi Pasteur SA offer, along with Fluarix Tetra, Fluarix QUADRIVALENT, Pandemrix, Fluarix, and FluLaval. Therefore, the availability of alternatives that can be utilized to treat the disease hinders the expansion of the market for influenza treatments.

Market Opportunities

High Potential for Expansion in Emerging Markets

Emerging markets offer influenza drug producers lucrative opportunities to expand their businesses. The dynamic life sciences sector fuels market expansion in developing nations like India and China. The market is also growing because of a rise in awareness of major problems brought on by influenza and a rise in the knowledge of early influenza identification. Additionally, improvements in developing nations' healthcare industries are anticipated to support market expansion. Due to the high patient population for the virus, developing nations in the Asia-Pacific region and LAMEA also present a significant market opportunity for the anti-influenza treatment market.

Regional Analysis

Based on region, the global influenza treatment market is bifurcated into North America, Europe, Asia-Pacific, and LAMEA.

North America Dominates the Global Market

North America is the most significant global influenza treatment market shareholder and is estimated to exhibit a CAGR of 3.9% over the forecast period. An increase in prevalence causes a surge in demand for medications used to treat influenza in the region. Another important element driving the expansion of the influenza treatment industry in the area is government guidelines about using antiviral medications. For instance, the U.S. Food and Drug Administration (FDA) advises against the use of four antiviral medications in the country during the flu season: Peramivir, Zanamivir, Oseltamivir Phosphate, and Baloxavir marboxil. As a result, the demand for such medications in the area increases. In addition, the region's simple access to antiviral medications and increased healthcare costs are two additional variables supporting the market's expansion.

North America held the greatest market share for influenza treatments and is predicted to keep doing so during the projected period Due to the region's rising frequency of influenza infection. A major aspect that helps the market's expansion is the rise in knowledge surrounding the early identification of medical conditions for better treatment. Another important factor driving market expansion in the area is the surge in R&D expenditures for antiviral medications used to treat influenza. For instance, Pimodivir, a chemical developed by Johnson & Johnson (Janssen Pharmaceuticals) for the treatment of influenza, is currently in phase III of research. As a result, the market for influenza therapy is growing due to the considerations listed above.

Europe is predicted to exhibit a CAGR of 5.6% over the forecast period. The rise in the number of people in Europe getting infected with the influenza virus is one factor contributing to the increase in the market for influenza treatment in Europe. Antiviral medications, essential in treating the underlying medical condition, have become more necessary due to this sharp rise in incidence. These antiviral pharmaceuticals are essential in the care of the underlying medical condition. The presence of the great majority of notable competitors in the region, which results in medicines being widely accessible, is another element that contributes to the expansion of the industry.

In Asia-Pacific, the presence of a sizable patient population and an increase in awareness associated with the early detection of the medical problem present potential opportunities for the key companies currently engaged in market competition. The rising cost of medical care is another significant factor supporting the sector's expansion. The number of people getting sick with the flu in the Asia-Pacific region also fuels the market's growth for flu medications. Another significant element that supports the market's growth is the rising expense of medical care and the associated increase in awards related to the use of influenza treatment.

LAMEA is a growing market, as healthcare expenditures are expected to increase over the forecast period, presenting industry participants with lucrative growth opportunities. The high prevalence of influenza infections is among the most important factors influencing this region's market expansion. Due to economic reforms that raised living standards and created new opportunities for the research and healthcare industries, this region has experienced the greatest economic growth over the past two decades.

Segmental Analysis

The global influenza treatment market is bifurcated into product and distribution channels.

Based on the product, the global influenza treatment Market is bifurcated into Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil, and others.

The Oseltamivir Phosphate segment dominates the global market and is projected to exhibit a CAGR of 3.91% over the forecast period. An oral antiviral medication called oseltamivir phosphate has been licensed to treat uncomplicated influenza. The FDA has approved the neuraminidase inhibitor medicinal compound. The medication also prevents the neuraminidase enzyme's expression on the influenza virus's surface. In addition, Oseltamivir phosphate stops the spread of infection by inhibiting the neuraminidase enzyme, which promotes the movement of viruses inside the respiratory tract. This is made possible by the virus becoming trapped inside the membrane of infected cells. Respiratory secretions can significantly impact how the virus is contained within the infected cell. F. Hoffmann-La Roche AG sells oseltamivir phosphate under the trade name Tamiflu, which is indicated to patients two weeks of age and older with flu symptoms lasting no longer than two days.

The advantages that the drug offers are among the variables that support the expansion of this market. For instance, Oseltamivir Phosphate can shield those above the age of one against the flu. The FDA has also classified the medication as pregnancy category C, indicating that pregnant women may also use it. In treating influenza, the medication's advantages outweigh any possible hazards. Therefore, these aspects make this medication a recommended option for treating influenza among doctors.

Based on distribution channels, the global influenza treatment market is segmented into retail pharmacy, hospital pharmacy, and others.

The hospital pharmacy segment owns the highest market share and is predicted to exhibit a CAGR of 3.6% during the forecast period. A "hospital pharmacy" is a type of pharmacy that is located inside a hospital or other medical facility. Inpatient pharmacies are another name for hospital pharmacies. These businesses are called "hospital pharmacies" because they are close to hospitals. All facets of the pharmaceutical sector, including the preparation, storage, and distribution of pharmaceuticals, are handled by these specialists, who are also in charge of the drugs. These facilities also oversee activities outside operations, like medical equipment storage. On top of the existing operations, this obligation is added.

Additionally, it is the duty of pharmacists employed by hospitals to instruct patients and other medical professionals on how to use medical equipment and pharmaceuticals most safely and efficiently possible. Similarly, these businesses are responsible for storing and distributing anti-viral drugs, typically given by medical professionals to those with the flu virus. These medicines are available from these companies to those with the flu virus. This segment is expanding due to several factors, including an increase in the number of influenza patients who need hospitalization, a sharp rise in the number of hospital pharmacies, and an improvement in the organizational design of hospital pharmacies in developing countries like China and India.

Recent Developments

• July 2022-Seqirus and a business of CSL Limited partnered for multi-year influenza medication research with the University of Liverpool Pandemic Institute. Seqirus would participate in research projects, inform the generation of the threat of seasonal influenza, and develop innovative approaches to the pandemic response.